{{Chembox
| ImageFile = Foretinib.svg
| ImageSize = 250px
| IUPACName = N1’-[3-fluoro-4-<nowiki>[[</nowiki>6-methoxy-7-(3-morpholinopropoxy)-4-quinolyl]oxy]phenyl]-N1-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
| OtherNames = XL880; EXEL-2880; GSK1363089; GSK089
|Section1={{Chembox Identifiers
| CASNo = 849217-64-7
| CASNo_Ref = {{cascite|correct|CAS}}
| PubChem = 
| ChemSpiderID = 24608641
| ChEMBL = 1908393
| UNII = 81FH7VK1C4
| KEGG = D09618
| SMILES = COc1cc2c(ccnc2cc1OCCCN3CCOCC3)Oc4ccc(cc4F)NC(=O)C5(CC5)C(=O)Nc6ccc(cc6)F
| InChI = InChI=1S/C34H34F2N4O6/c1-43-30-20-25-27(21-31(30)45-16-2-13-40-14-17-44-18-15-40)37-12-9-28(25)46-29-8-7-24(19-26(29)36)39-33(42)34(10-11-34)32(41)38-23-5-3-22(35)4-6-23/h3-9,12,19-21H,2,10-11,13-18H2,1H3,(H,38,41)(H,39,42)
  }}
|Section2={{Chembox Properties
| C=34 | H=34 | F=2 | N=4 | O=6
| Appearance = 
| Density = 
| MeltingPt = 
| BoilingPt = 
| Solubility =
  }}
|Section3={{Chembox Hazards
| MainHazards = 
| FlashPt = 
| AutoignitionPt =
  }}
}}

'''Foretinib''' is an experimental drug candidate for the treatment of cancer.<ref>{{cite journal |author1=Hedgethorne, K. |author2=Huang, P.H. | title = Foretinib.  c-Met and VEGFR-2 inhibitor, Oncolytic | journal = Drugs Fut | year = 2010 | volume = 35 | issue = 11 | pages = 893–901 | doi = 10.1358/dof.2010.35.11.1529012|doi-broken-date=2017-01-15 }}</ref>  It was discovered by [[Exelixis]] and is under development by [[GlaxoSmithKline]].<ref name=PL>{{cite web | url = http://www.exelixis.com/pipeline/xl880 | title = XL880 (GSK1363089) | publisher = Exelixis, Inc}}</ref>  About 10 Phase II clinical trials have been run.<ref name=CTF>{{cite web| url = http://clinicaltrials.gov/ct2/results?term=Foretinib+ | title = Foretinib | publisher = clinicaltrials.gov}}</ref> {{As of |2015|10}} it appears development has been discontinued.<ref>http://adisinsight.springer.com/drugs/800022245</ref>

Foretinib is an [[tyrosine-kinase inhibitor|inhibitor of the kinase enzymes]] [[c-Met]] and [[vascular endothelial growth factor receptor 2]] (VEGFR-2).<ref name=Qian2009>{{cite journal | pmid = 19808973 | year = 2009 | last1 = Qian | first1 = F | last2 = Engst | first2 = S | last3 = Yamaguchi | first3 = K | last4 = Yu | first4 = P | last5 = Won | first5 = KA | last6 = Mock | first6 = L | last7 = Lou | first7 = T | last8 = Tan | first8 = J | last9 = Li | first9 = C | last10 = Tam | first10 = D. | last11 = Lougheed | first11 = J. | last12 = Yakes | first12 = F. M. | last13 = Bentzien | first13 = F. | last14 = Xu | first14 = W. | last15 = Zaks | first15 = T. | last16 = Wooster | first16 = R. | last17 = Greshock | first17 = J. | last18 = Joly | first18 = A. H. | title = Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases | volume = 69 | issue = 20 | pages = 8009–16 | doi = 10.1158/0008-5472.CAN-08-4889 | journal = Cancer Research| display-authors = 8 }}</ref>

==See also==
*[[c-Met inhibitors]]
*[[Cabozantinib]], a similar molecule and kinase inhibitor with FDA approval
*[[VEGFR inhibitor]]
*[[tyrosine-kinase inhibitor]]

==References==
{{Reflist}}

{{Growth factor receptor modulators}}

[[Category:Tyrosine kinase inhibitors]]
[[Category:Quinolines]]
[[Category:Morpholines]]
[[Category:Cyclopropanes]]
[[Category:Fluoroarenes]]
[[Category:Abandoned drugs]]